<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02522754</url>
  </required_header>
  <id_info>
    <org_study_id>IDB 004 IDB 005</org_study_id>
    <nct_id>NCT02522754</nct_id>
  </id_info>
  <brief_title>Development of an Intranasal Proteosome Influenza Vaccine</brief_title>
  <official_title>Study to Determine if Intranasal Proteosome-Adjuvanted Trivalent Influenza Vaccine is Safe, Immunogenic and Efficacious in the Influenza Human Viral Challenge Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvivo</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hvivo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to compare multiple dosage regimes of a protesomal intranasal vaccine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Proteosome-adjuvanted trivalent inactivated influenza vaccine (P-TIV) administered
      intra-nasally was shown to be effective, safe, well tolerated, immunogenic - in both systemic
      and mucosal compartments - and effective at preventing influenza illness.

      In two separate studies using the Human Viral Challenge Model, subjects were selected for
      susceptibility to A/Panama/2007/1999 (H3N2) virus and then dosed with one of three regimens:
      (A/New Caledonia/20/1999 (H1N1), A/Panama/2007/1999 (H3N2), B/Victoria/504/2000 or
      B/Shangdong/7/1997) or placebo via a nasal spray. One or two doses were given, 14 days apart,
      before subjects were challenged with ~8.5 x 105 EID¬50 of A/Panama/2007/1999 (H3N2) virus.
      Immune responses to the vaccine antigens were measured, namely serum IgG (via the
      aemagglutination inhibition assay (HAI)) and nasal wash secretory IgA (sIgA) antibodies (via
      ELISA). Viral titres in nasal washes and symptoms of influenza illness were assessed after
      viral challenge and compared.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Actual">January 2004</completion_date>
  <primary_completion_date type="Actual">January 2004</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Influenza Like Illness in those with laboratory confirmed influenza</measure>
    <time_frame>Within the duration of infection, approx 10 days</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">174</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protesomal Vaccine 1 x 30 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Protesomal Vaccine 1 x 30 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protesomal Vaccine 2 x 30 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Protesomal Vaccine 2 x 30 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protesomal Vaccine 2 x 15 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Protesomal Vaccine 2 x 15 µg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo Protesomal Vaccine</intervention_name>
    <description>Intranasal vaccine Protesomal Vaccine</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Experimental: Protesomal Vaccine 1 x 30 µg</intervention_name>
    <description>Experimental: Protesomal Vaccine 1 x 30 µg</description>
    <arm_group_label>Protesomal Vaccine 1 x 30 µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Experimental: Protesomal Vaccine 2 x 30 µg</intervention_name>
    <description>Experimental: Protesomal Vaccine 2 x 30 µg</description>
    <arm_group_label>Protesomal Vaccine 2 x 30 µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Experimental: Protesomal Vaccine 2 x 15 µg</intervention_name>
    <description>Experimental: Protesomal Vaccine 2 x 15 µg</description>
    <arm_group_label>Protesomal Vaccine 2 x 15 µg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Young healthy adults as determined by medical history, physical examination, serology
             (HIV and Hepatitis B and C) and clinical laboratory tests.

          -  Female subjects were required to provide of a history of reliable contraceptive
             practice.

          -  Susceptibility to A/Panama/2007/1999 (H3N2) (a serum reciprocal HAI titre ≤10) was
             confirmed at screening. -

        Exclusion Criteria:included;

          -  asthma,

          -  hypersensitivity to mercurials or chicken eggs,

          -  anatomic or neurologic abnormality impairing the gag reflex or contributing to
             aspiration, * chronic nasopharyngeal complaints,

          -  abnormal electrocardiogram (ECG),

          -  febrile illness or significant symptoms of upper respiratory infection on the day of
             vaccination or between admission to quarantine and administration of the challenge
             inoculum.

          -  Subjects using medication or other products for rhinitis or nasal congestion,

          -  Subject who had received systemic glucocorticoids within 1 month, or cytotoxic or
             immunosuppressive drugs within 6 months of the study start.

          -  Subjects agreed not to smoke during the quarantine phase.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rob Lambkin-Williams, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PI</affiliation>
  </overall_official>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2015</study_first_submitted>
  <study_first_submitted_qc>August 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2015</study_first_posted>
  <last_update_submitted>August 12, 2015</last_update_submitted>
  <last_update_submitted_qc>August 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hvivo</investigator_affiliation>
    <investigator_full_name>R Lambkin-Williams</investigator_full_name>
    <investigator_title>Chief Scientist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

